Organogenesis Holdings Inc. (ORGO) Fair Value 2026

ORGO · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.0 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (19/100)

Quick Summary — As of 2026-08-28, Organogenesis Holdings Inc. (ORGO) trades at $1.74, versus a $2.21 median fair value across its 9 active models — 27.1% above the current price. QOC: 8.0/10. Value Trap Risk: 19/100 (SAFE). 9/13 models active.

Key Facts

Ticker
ORGO
Price
$1.74
Quality Score
8.0/10
Value Trap Risk
19/100
Models Active
9/13
Last Updated
Strength: First Chicago suggests +370.2% upside with 56% confidence
Risk: Limited model coverage (9/13) may reduce confidence

Is Organogenesis Holdings Inc. (ORGO) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Organogenesis Holdings Inc. (ORGO) appears undervalued as of : the median of 9 independent fair value estimates is $2.21, 27.1% above the current price of $1.74. Estimates range from $0.20 to $8.18. ORGO scores 8.0/10 on fundamental quality and 19/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. ORGO’s +27.1% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -8.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Organogenesis Holdings Inc. Stock in 2026? →

What Fair Value Does Each Model Give ORGO?

9 Intrinsic Value Models vs. Current Price ($1.74)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.46 -73.3%
Ensemble · Low Conviction
 $2.21 +27.1%
Scenario · High Conviction
 $8.18 +370.2%
Intrinsic · High Conviction
 $2.12 +21.6%
Unlock the Full Matrix

Access 5 additional models including PWERM, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is ORGO's Fair Value Range?

Spread across 9 independent models · $0.20 to $8.18

CirclFi's 9 active models place Organogenesis Holdings Inc. (ORGO) between $0.20 and $8.18 per share, a spread of 361% of the median. The median of that range — $2.21 — is the fair value CirclFi publishes for ORGO, against a current price of $1.74.

Low · RCMH-DCFHigh · First Chicago
$0.20median $2.21$8.18
Where the range comes from
Most bearish modelRCMH-DCF$0.20
Most bullish modelFirst Chicago$8.18
Model agreement7 bullish · 2 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for ORGO. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on ORGO, not a CirclFi price target. How each model works →

What Is Organogenesis Holdings Inc. (ORGO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Organogenesis Holdings Inc. is potentially undervalued at its current price of $1.74. Based on our 13-model framework, Organogenesis Holdings Inc.'s intrinsic value is estimated at a median fair value of $2.21 — representing +27.1% implied upside — with 7 out of 9 active models confirming this thesis. Model dispersion is worth noting: First Chicago targets $8.18 (+370.2%), versus RCMH-DCF at $0.20 (-88.2%). This +458.4% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About ORGO?

9 of 13 models are currently active for ORGO. Of these, 7 models suggest upside while 2 models suggest overvaluation. Taken together, their median fair value for ORGO is $2.21 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ORGO Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, ORGO ranks #19 by Quality of Company score. CirclFi's QOC score of 8.0/10 evaluates 32 fundamental signals. A score of 8.0 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

As a biopharma enterprise, Organogenesis Holdings Inc. operates in a sector where revenue per drug is a critical driver of valuation. Investors evaluating ORGO should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ORGO a Value Trap?

CirclFi's Value Trap algorithm assigns ORGO a score of 19/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Organogenesis Holdings Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Organogenesis Holdings Inc.'s fundamental quality profile registers 8.0/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +458.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ORGO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ORGO's 9 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Organogenesis Holdings Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

KNSAKiniksa Pharmaceuticals International, plcQOC 8.1XERSXeris Biopharma Holdings, Inc.QOC 7.9AMRXAmneal Pharmaceuticals, Inc.QOC 8.3HIMSHims & Hers Health, Inc.QOC 7.9PBHPrestige Consumer Healthcare Inc.QOC 8.3PCRXPacira BioSciences, Inc.QOC 7.8DERMJourney Medical CorporationQOC 6.2IMCCIM Cannabis Corp.QOC 5.2NIKANIKA PHARMACEUTICALS INC.QOC 3.5UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: KNSA · XERS · AMRX · HIMS · PBH · PCRX · DERM · IMCC · NIKA · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to ORGO?

7 companies across all industries closest to ORGO’s Quality of Company score of 8.0/10.

RMBIRichmond Mutual Bancorporation, Inc.QOC 8.0FLOCFlowco Holdings Inc.QOC 8.0LUXELuxExperience B.V.QOC 8.0CNQCanadian Natural Resources LimitedQOC 8.0CZFSCitizens Financial Services, Inc.QOC 8.0LTCLTC Properties, Inc.QOC 8.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RMBI · FLOC · LUXE · CNQ · CZFS · LTC · NVDA

Where Does ORGO Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

ORGO is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Organogenesis Holdings Inc.’s Valuation?

What is Organogenesis Holdings Inc.'s intrinsic value in 2026?

CirclFi puts Organogenesis Holdings Inc. (ORGO)'s intrinsic value at $2.21 — the median of 9 independent model estimates as of 2026-08-28, ranging from $0.20 to $8.18. The Quality of Company score is 8.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ORGO overvalued or undervalued right now?

At $1.74, 7 of 9 active models suggest ORGO may be undervalued, while 2 indicate potential overvaluation. The median of all 9 fair value estimates is $2.21, 27.1% above the current price of $1.74 — a consensus view that ORGO is undervalued. The assessment depends on which methodology best fits Organogenesis Holdings Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 8.0 mean for ORGO?

Organogenesis Holdings Inc.'s QOC of 8.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on ORGO?

CirclFi analyzes ORGO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ORGO?

Of the 9 models currently active on ORGO, First Chicago is the most bullish at $8.18 per share, and RCMH-DCF is the most bearish at $0.20. CirclFi's published fair value for ORGO is the median of that range, $2.21, not either extreme. The gap between the two ends equals 361% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is ORGO a value trap in 2026?

Organogenesis Holdings Inc.'s Value Trap score is 19/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Organogenesis Holdings Inc. (ORGO) has a median fair value of $2.21 — 27.1% above the current price of $1.74 — as of 2026-08-28.” Source: circlfi.com/stock/ORGO/ · Methodology
Primary sources for this ORGO valuation
  • Financial statements: Organogenesis Holdings Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001661181) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ORGO as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on ORGO.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for ORGO Unlock All 9 — $39/mo